{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T01:00:34Z","timestamp":1783472434427,"version":"3.55.0"},"reference-count":19,"publisher":"S. Karger AG","issue":"3","license":[{"start":{"date-parts":[[2013,1,1]],"date-time":"2013-01-01T00:00:00Z","timestamp":1356998400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.karger.com\/Services\/SiteLicenses"},{"start":{"date-parts":[[2013,1,1]],"date-time":"2013-01-01T00:00:00Z","timestamp":1356998400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.karger.com\/Services\/SiteLicenses"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Int Arch Allergy Immunol"],"published-print":{"date-parts":[[2013]]},"abstract":"<b><i>Background:<\/i><\/b> The population of large parts of Africa, South America and travellers to these areas are at risk of yellow fever (YF) with a 50% mortality risk. Yellow fever vaccine (YFV) propagated in hens' eggs confers protection in 95% of the vaccinated. The rate of anaphylaxis for YFV ranges from 0.42 to 1.8\/100,000 doses with most cases considered to be due to egg allergy. Egg allergy is a contraindication for the YFV. Nevertheless, the potential fatal sequelae from YF give the incentive to protect everyone at risk irrespective of their allergic status. <b><i>Methods:<\/i><\/b> Six subjects who had had a recent reaction to egg and who were travelling to endemic areas (3 adults and 3 children) underwent skin prick tests (SPT) with undiluted YFV and egg extract. Intradermal tests for YFV were undertaken at a 1:10 dilution. In 4 egg-allergic patients with a positive SPT to YFV, a 7-step desensitization protocol was used. A 2-step (10 + 90%) protocol was used in the 2 subjects with a negative YFV SPT. Premedication was not administered. <b><i>Results:<\/i><\/b> All 6 patients were successfully vaccinated. Four patients completed desensitization: 1 developed mild local erythema at the injection site, 1 had fleeting generalized urticaria with local erythema\/angioedema and 2 did not experience any adverse reactions. Patients who received YFV in 2 steps developed no adverse reactions. <b><i>Conclusions:<\/i><\/b> We describe the successful administration of YFV in 6 egg-allergic patients. The Cambridge Allergy 7-step protocol allows for its safe administration in patients with positive SPT to YFV. A 2-step protocol can be used in patients with negative YFV SPT.<\/jats:p>","DOI":"10.1159\/000346350","type":"journal-article","created":{"date-parts":[[2013,3,15]],"date-time":"2013-03-15T14:39:09Z","timestamp":1363358349000},"page":"274-278","source":"Crossref","is-referenced-by-count":36,"title":["Administration of Yellow Fever Vaccine in Patients with Egg Allergy"],"prefix":"10.1159","volume":"161","author":[{"given":"K.","family":"Rutkowski","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.W.","family":"Ewan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.M.","family":"Nasser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"127","published-online":{"date-parts":[[2013,3,15]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1517%2F14740330902808086"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016%2Fj.jaci.2012.04.003"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016%2Fj.vaccine.2005.01.089"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1111%2Fj.1398-9995.2009.02205.x"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016%2Fj.vaccine.2008.09.009"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016%2FS0091-6749%2899%2970245-9"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1034%2Fj.1398-9995.2002.13027.x"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1034%2Fj.1600-0536.2001.450601.x"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1111%2Fj.1365-2222.2010.03557.x"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1097%2FACI.0b013e3283464d1b"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.4172%2F2155-6121.S3-002"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016%2Fj.vaccine.2009.02.049"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016%2FS0022-3476%2898%2970101-5"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1016%2Fj.jaci.2010.05.037"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016%2Fj.anai.2010.08.015"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016%2Fj.jaci.2010.02.013"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016%2FS0091-6749%2899%2970136-3"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1016%2FS0091-6749%2897%2970154-4"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1016%2FS0091-6749%2896%2980191-6"}],"container-title":["International Archives of Allergy and Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/346350","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/346350","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,23]],"date-time":"2025-04-23T18:45:34Z","timestamp":1745433934000},"score":1,"resource":{"primary":{"URL":"https:\/\/karger.com\/article\/doi\/10.1159\/000346350"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013]]},"references-count":19,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2013,6,1]]},"published-print":{"date-parts":[[2013,6,13]]}},"URL":"https:\/\/doi.org\/10.1159\/000346350","archive":["Portico"],"relation":{},"ISSN":["1018-2438","1423-0097"],"issn-type":[{"value":"1018-2438","type":"print"},{"value":"1423-0097","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013]]}}}